Cite
HARVARD Citation
Wen, P. et al. (n.d.). P05.06 Phase 2 study to evaluate the safety, pharmacokinetics and clinical activity of PI3K/mTOR inhibitor GDC-0084 given to glioblastoma (GBM) patients with unmethylated O6-methylguanine-methyltransferase (MGMT) promoter status. Neuro-oncology. p. iii35. [Online].